155 related articles for article (PubMed ID: 35349227)
1. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C; Voutsinas JM; Wu QV; Santana-Davila R; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
Cancer Med; 2022 Nov; 11(22):4104-4111. PubMed ID: 35349227
[TBL] [Abstract][Full Text] [Related]
2. High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
Chalker C; Santana-Davila R; Voutsinas JM; Wu QV; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
J Palliat Med; 2022 Apr; 25(4):614-619. PubMed ID: 34847733
[No Abstract] [Full Text] [Related]
3. Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors.
Pan C; Wu QV; Voutsinas J; Houlton JJ; Barber B; Rizvi ZH; Marchiano E; Futran N; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Fromm JR; Rodriguez CP
Cancer Med; 2023 Apr; 12(8):9384-9391. PubMed ID: 36806947
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
[TBL] [Abstract][Full Text] [Related]
5. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
6. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
9. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
11. Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.
Issa M; Klamer BG; Mladkova N; Laliotis GI; Karivedu V; Bhateja P; Byington C; Dibs K; Pan X; Chakravarti A; Grecula J; Jhawar SR; Mitchell D; Baliga S; Old M; Carrau RL; Rocco JW; Blakaj DM; Bonomi M
BMC Cancer; 2022 Jul; 22(1):767. PubMed ID: 35836204
[TBL] [Abstract][Full Text] [Related]
12. Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Alkhatib HH; Maroun CA; Guller M; Cooper DJ; Wu ES; Eisele DW; Fakhry C; Pardoll D; Seiwert TY; Zhu G; Mandal R
Otolaryngol Head Neck Surg; 2024 Mar; 170(3):828-836. PubMed ID: 38123496
[TBL] [Abstract][Full Text] [Related]
13. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.
Pestana RC; Becnel M; Rubin ML; Torman DK; Crespo J; Phan J; Hanna E; Bell D; Glisson BS; Johnson JM; Lee JJ; Ferrarotto R
Oral Oncol; 2020 Feb; 101():104523. PubMed ID: 31864957
[TBL] [Abstract][Full Text] [Related]
14. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
In Vivo; 2022; 36(2):907-917. PubMed ID: 35241549
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
[TBL] [Abstract][Full Text] [Related]
16. Ultra-high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma.
Saito Y; Kobayashi K; Fukuoka O; Sakai T; Yamamura K; Ando M; Kondo K
Head Neck; 2024 Feb; 46(2):367-377. PubMed ID: 38063247
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study.
Søby S; Gothelf A; Gyldenkerne N; Bentzen J; Nowicka-Matus K; Tramm T; Eriksen JG
Acta Oncol; 2022 Aug; 61(8):972-978. PubMed ID: 35913523
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
19. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
Saleh K; Auperin A; Martin N; Borcoman E; Torossian N; Iacob M; Ferrand FR; Khalife N; Baste N; Guigay J; Le Tourneau C; Daste A; Saada-Bouzid E; Even C
Eur J Cancer; 2021 Nov; 157():190-197. PubMed ID: 34536943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
